Violet Light-Filtering IOLs & Glaucoma Vision
New Data Suggests Lower risk of Diabetic Retinopathy with Faricimab
Table of Contents
New data presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 annual meeting suggest that faricimab-svoa (Vabysmo, Genentech/Roche) may be associated with a lower risk of diabetic retinopathy (DR) progression compared with aflibercept (Eylea, Regeneron). The findings come from a post-hoc analysis of the pivotal phase 3 GALILEO and YOSEMITE trials.
Key Findings from ARVO 2024
Researchers analyzed data from patients with diabetic macular edema (DME) who participated in the GALILEO and YOSEMITE trials. The analysis focused on the incidence of DR progression, defined as a two-step worsening in DR severity scale (DRSS) during the trials.
Here’s a breakdown of the key takeaways:
Reduced Progression: Patients treated with faricimab experienced a substantially lower rate of DR progression compared to those treated with aflibercept. Specifically, the risk of DR progression was reduced by 26% with faricimab.
Consistent Across Subgroups: This benefit was observed across various subgroups, including patients with and without prior anti-VEGF treatment, as well as those with different baseline DR severity levels.
Visual Acuity Gains: Both faricimab and aflibercept demonstrated improvements in visual acuity, but the reduced DR progression with faricimab offers an additional potential benefit for patients.
Treatment Burden: Faricimab’s less frequent dosing schedule (every 2-4 months after loading dose) compared to aflibercept (every month) could also contribute to a reduced treatment burden for patients.
Understanding the Implications for Diabetic Retinopathy Management
Diabetic retinopathy remains a leading cause of vision loss worldwide. Early detection and timely treatment are crucial to prevent vision impairment. the findings from this analysis add to the growing body of evidence supporting faricimab as a valuable treatment option for DME.
“these data are encouraging, as they suggest that faricimab not only improves visual acuity in patients with DME but may also help to slow the progression of the underlying retinal disease,” said Dr. Vendal,who was quoted in a healio report on the findings. “This is significant because DR progression can lead to irreversible vision loss.”
How Faricimab Works: A Dual-Action Approach
Faricimab is a bispecific antibody that together targets both VEGF-A and Ang-2.
VEGF-A Inhibition: VEGF-A is a key driver of vascular endothelial growth factor, promoting blood vessel growth and leakage in the retina. blocking VEGF-A helps to reduce edema and improve visual acuity.
ang-2 Inhibition: Ang-2 plays a role in vascular instability and inflammation. By inhibiting Ang-2,faricimab aims to stabilize blood vessels and further reduce retinal damage.
This dual-action mechanism is thought to contribute to faricimab’s efficacy in treating DME and potentially slowing DR progression.
What This Means for You
If you’ve been diagnosed with DME, it’s important to discuss all available treatment options with your ophthalmologist. Faricimab may be a suitable option, particularly if you’re looking for a treatment that could potentially slow the progression of your retinopathy in addition to improving your vision.
Remember to:
Attend regular eye exams: Early detection is key to managing DR.
Follow your doctor’s treatment plan: Adhering to your prescribed treatment regimen is crucial for optimal outcomes.
* Manage your diabetes: Maintaining good blood sugar control is essential for preventing and slowing the progression of DR.
Vendal reports consulting for Johnson & Johnson.